WBA Stock Recent News

Walgreens Boots Alliance Thursday reported a narrower-than-expected $178 million loss in its third quarter as the struggling pharmacy chain nears the end of its long run as a publicly traded company.

Walgreens previously said it was withdrawing its fiscal-year outlook after reaching a take-private deal with Sycamore Partners.

Shares of Walgreens Boots Alliance Inc. WBA rose 0.8% in premarket trades after the drugstore chain beat Wall Street's sales and adjusted profit expectations in its fiscal third-quarter results.

Walgreens Boots Alliance , which is being taken private by Sycamore Partners, beat analysts' estimates for third-quarter profit on Thursday, as store closures and cost-cutting aided turnaround efforts at the second-largest U.S. pharmacy chain.

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the third quarter of fiscal 2025, which ended May 31, 2025. Chief Executive Officer Tim Wentworth said: “Third quarter results reflect continued improvement in our U.S. Healthcare segment and benefits from our cost savings initiatives, while we continued to see weakness in our U.S. front-end sales. We remain focused on our turnaround plan, which will require time, disciplined foc.

Walgreens Boots Alliance, Inc. WBA will release earnings results for the third quarter, before the opening bell on Thursday, June 26.

TAMPA, Fla.--(BUSINESS WIRE)-- #PrEP--On National HIV Testing Day, CAN Community Health is partnering with Walgreens to support the national ‘Greater Than HIV' campaign. This initiative provides free, confidential HIV testing at Walgreens locations nationwide on Friday, June 27, 2025. As part of this national initiative, CAN Community Health mobile units will be stationed at select Walgreens locations across the country, offering on-site HIV testing, prevention education, and linkage to care. According.

Get a deeper insight into the potential performance of Walgreens (WBA) for the quarter ended May 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Walgreens faces a buyout by Sycamore Partners after years of declining profitability, heavy debt, and failed strategic pivots in a rapidly changing retail pharmacy landscape. Shareholders are offered $11.45 per share plus a potential $3 per share from future VillageMD asset sales, but the latter payout is uncertain and risky. The deal is not finalized; Q3 earnings and the upcoming shareholder vote are key, but the company's long-term prospects as a public entity appear bleak.

Dividend growth investing is a powerful way to compound wealth and set yourself up for financial independence. However, it also has some real drawbacks. I share 3 aspects of the dark side of dividend growth investing in this article.